Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 172

1.
2.

Impact of recent screening on predicting the outcome of prostate cancer biopsy in men with elevated prostate-specific antigen: data from the European Randomized Study of Prostate Cancer Screening in Gothenburg, Sweden.

Vickers AJ, Cronin AM, Aus G, Pihl CG, Becker C, Pettersson K, Scardino PT, Hugosson J, Lilja H.

Cancer. 2010 Jun 1;116(11):2612-20. doi: 10.1002/cncr.25010.

3.

Reducing unnecessary biopsy during prostate cancer screening using a four-kallikrein panel: an independent replication.

Vickers A, Cronin A, Roobol M, Savage C, Peltola M, Pettersson K, Scardino PT, Schröder F, Lilja H.

J Clin Oncol. 2010 May 20;28(15):2493-8. doi: 10.1200/JCO.2009.24.1968. Epub 2010 Apr 26.

4.

A four-kallikrein panel predicts prostate cancer in men with recent screening: data from the European Randomized Study of Screening for Prostate Cancer, Rotterdam.

Vickers AJ, Cronin AM, Roobol MJ, Savage CJ, Peltola M, Pettersson K, Scardino PT, Schröder FH, Lilja H.

Clin Cancer Res. 2010 Jun 15;16(12):3232-9. doi: 10.1158/1078-0432.CCR-10-0122. Epub 2010 Apr 16.

5.

A panel of kallikrein markers can reduce unnecessary biopsy for prostate cancer: data from the European Randomized Study of Prostate Cancer Screening in Göteborg, Sweden.

Vickers AJ, Cronin AM, Aus G, Pihl CG, Becker C, Pettersson K, Scardino PT, Hugosson J, Lilja H.

BMC Med. 2008 Jul 8;6:19. doi: 10.1186/1741-7015-6-19.

6.

A four-kallikrein panel for the prediction of repeat prostate biopsy: data from the European Randomized Study of Prostate Cancer screening in Rotterdam, Netherlands.

Gupta A, Roobol MJ, Savage CJ, Peltola M, Pettersson K, Scardino PT, Vickers AJ, Schröder FH, Lilja H.

Br J Cancer. 2010 Aug 24;103(5):708-14. doi: 10.1038/sj.bjc.6605815. Epub 2010 Jul 27.

7.

Predictive value of four kallikrein markers for pathologically insignificant compared with aggressive prostate cancer in radical prostatectomy specimens: results from the European Randomized Study of Screening for Prostate Cancer section Rotterdam.

Carlsson S, Maschino A, Schröder F, Bangma C, Steyerberg EW, van der Kwast T, van Leenders G, Vickers A, Lilja H, Roobol MJ.

Eur Urol. 2013 Nov;64(5):693-9. doi: 10.1016/j.eururo.2013.04.040. Epub 2013 May 2.

8.

The added value of percentage of free to total prostate-specific antigen, PCA3, and a kallikrein panel to the ERSPC risk calculator for prostate cancer in prescreened men.

Vedder MM, de Bekker-Grob EW, Lilja HG, Vickers AJ, van Leenders GJ, Steyerberg EW, Roobol MJ.

Eur Urol. 2014 Dec;66(6):1109-15. doi: 10.1016/j.eururo.2014.08.011. Epub 2014 Aug 26.

9.

A panel of kallikrein marker predicts prostate cancer in a large, population-based cohort followed for 15 years without screening.

Vickers AJ, Gupta A, Savage CJ, Pettersson K, Dahlin A, Bjartell A, Manjer J, Scardino PT, Ulmert D, Lilja H.

Cancer Epidemiol Biomarkers Prev. 2011 Feb;20(2):255-61. doi: 10.1158/1055-9965.EPI-10-1003. Epub 2010 Dec 8.

10.

Comparison Between the Four-kallikrein Panel and Prostate Health Index for Predicting Prostate Cancer.

Nordström T, Vickers A, Assel M, Lilja H, Grönberg H, Eklund M.

Eur Urol. 2015 Jul;68(1):139-46. doi: 10.1016/j.eururo.2014.08.010. Epub 2014 Aug 20.

11.

Predicting high-grade cancer at ten-core prostate biopsy using four kallikrein markers measured in blood in the ProtecT study.

Bryant RJ, Sjoberg DD, Vickers AJ, Robinson MC, Kumar R, Marsden L, Davis M, Scardino PT, Donovan J, Neal DE, Lilja H, Hamdy FC.

J Natl Cancer Inst. 2015 Apr 11;107(7). pii: djv095. doi: 10.1093/jnci/djv095. Print 2015 Jul.

12.

Prostate-specific antigen velocity for early detection of prostate cancer: result from a large, representative, population-based cohort.

Vickers AJ, Wolters T, Savage CJ, Cronin AM, O'Brien MF, Pettersson K, Roobol MJ, Aus G, Scardino PT, Hugosson J, Schröder FH, Lilja H.

Eur Urol. 2009 Nov;56(5):753-60. doi: 10.1016/j.eururo.2009.07.047. Epub 2009 Aug 7.

13.

An empirical evaluation of guidelines on prostate-specific antigen velocity in prostate cancer detection.

Vickers AJ, Till C, Tangen CM, Lilja H, Thompson IM.

J Natl Cancer Inst. 2011 Mar 16;103(6):462-9. doi: 10.1093/jnci/djr028. Epub 2011 Feb 24.

14.

Can one blood draw replace transrectal ultrasonography-estimated prostate volume to predict prostate cancer risk?

Carlsson SV, Peltola MT, Sjoberg D, Schröder FH, Hugosson J, Pettersson K, Scardino PT, Vickers AJ, Lilja H, Roobol MJ.

BJU Int. 2013 Sep;112(5):602-9. doi: 10.1111/j.1464-410X.2012.11690.x. Epub 2013 Feb 28.

15.

Prediction of prostate cancer risk: the role of prostate volume and digital rectal examination in the ERSPC risk calculators.

Roobol MJ, van Vugt HA, Loeb S, Zhu X, Bul M, Bangma CH, van Leenders AG, Steyerberg EW, Schröder FH.

Eur Urol. 2012 Mar;61(3):577-83. doi: 10.1016/j.eururo.2011.11.012. Epub 2011 Nov 15.

PMID:
22104592
16.

Prostate cancer screening in men aged 50-69 years (STHLM3): a prospective population-based diagnostic study.

Grönberg H, Adolfsson J, Aly M, Nordström T, Wiklund P, Brandberg Y, Thompson J, Wiklund F, Lindberg J, Clements M, Egevad L, Eklund M.

Lancet Oncol. 2015 Dec;16(16):1667-76. doi: 10.1016/S1470-2045(15)00361-7. Epub 2015 Nov 10.

PMID:
26563502
17.

Improving prostate cancer detection in veterans through the development of a clinical decision rule for prostate biopsy.

Hill OT, Mason TJ, Schwartz SW, Foulis PR.

BMC Urol. 2013 Jan 29;13:6. doi: 10.1186/1471-2490-13-6.

18.

Improving the Specificity of Screening for Lethal Prostate Cancer Using Prostate-specific Antigen and a Panel of Kallikrein Markers: A Nested Case-Control Study.

Stattin P, Vickers AJ, Sjoberg DD, Johansson R, Granfors T, Johansson M, Pettersson K, Scardino PT, Hallmans G, Lilja H.

Eur Urol. 2015 Aug;68(2):207-13. doi: 10.1016/j.eururo.2015.01.009. Epub 2015 Feb 11.

19.

Selective detection of histologically aggressive prostate cancer: an Early Detection Research Network Prediction model to reduce unnecessary prostate biopsies with validation in the Prostate Cancer Prevention Trial.

Williams SB, Salami S, Regan MM, Ankerst DP, Wei JT, Rubin MA, Thompson IM, Sanda MG.

Cancer. 2012 May 15;118(10):2651-8. doi: 10.1002/cncr.26396. Epub 2011 Oct 17.

20.

Use of low free to total PSA ratio in prostate cancer screening: detection rates, clinical and pathological findings in Brazilian men with serum PSA levels <4.0 ng/mL.

Faria EF, Carvalhal GF, dos Reis RB, Tobias-Machado M, Vieira RA, Reis LO, Nogueira L, Machado RD, Freitas CH Jr, Magnabosco WJ, Mauad EC, Carvalho AL.

BJU Int. 2012 Dec;110(11 Pt B):E653-7. doi: 10.1111/j.1464-410X.2012.11398.x. Epub 2012 Aug 14.

Items per page

Supplemental Content

Write to the Help Desk